Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May 1;27(9):2430-2434.
doi: 10.1158/1078-0432.CCR-20-3857. Epub 2021 Feb 9.

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations

R Donald Harvey #  1 , Suanna S Bruinooge #  2 , Li Chen  3 , Elizabeth Garrett-Mayer  4 , Whitney Rhodes  3 , Edward Stepanski  3 , Thomas S Uldrick  5 , Gwynn Ison  6 , Sean Khozin  7 , Wendy S Rubinstein  6 , Caroline Schenkel  4 , Robert S Miller  8 , George A Komatsoulis  8 , Richard L Schilsky #  4 , Edward S Kim #  9
Affiliations
Meta-Analysis

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations

R Donald Harvey et al. Clin Cancer Res. .

Abstract

Purpose: Cancer clinical trials often accrue slowly or miss enrollment targets. Strict eligibility criteria are a major reason. Restrictive criteria also limit opportunities for patient participation while compromising external validity of trial results. We examined the impact of broadening select eligibility criteria on characteristics and number of patients eligible for trials, using recommendations of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research.

Experimental design: A retrospective, observational analysis used electronic health record data from ASCO's CancerLinQ Discovery database. Study cohort included patients with advanced non-small cell lung cancer treated from 2011 to 2018. Patients were grouped by traditional criteria [no brain metastases, no other malignancies, and creatinine clearance (CrCl) ≥ 60 mL/minute] and broadened criteria (including brain metastases, other malignancies, and CrCl ≥ 30 mL/minute).

Results: The analysis cohort included 10,500 patients. Median age was 68 years, and 73% of patients were White. Most patients had stage IV disease (65%). A total of 5,005 patients (48%) would be excluded from trial participation using the traditional criteria. The broadened criteria, however, would allow 98% of patients (10,346) to be potential participants. Examination of patients included by traditional criteria (5,495) versus those added (4,851) by broadened criteria showed that the number of women, patients aged 75+ years, and those with stage IV cancer was significantly greater using broadened criteria.

Conclusions: This analysis of real-world data demonstrated that broadening three common eligibility criteria has the potential to double the eligible patient population and include trial participants who are more representative of those encountered in practice.See related commentary by Giantonio, p. 2369.

PubMed Disclaimer

Comment in

References

    1. Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, et al. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. J Clin Oncol. 2009;27:325s.
    1. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. 2010;143.
    1. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of Cancer Therapy Evaluation Program (NCI-CTEP) sponsored studies. Clin Cancer Res. 2010;16:5557–63.
    1. Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012;18:256–62.
    1. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010;28:5197–201.

Publication types

LinkOut - more resources